Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by Stylesson Aug 30, 2013 5:35pm

580 Views

Post# 21710704

RE:RE:RE:RE:RE:RE:A few tidbits

why not wittmann. A year ago i was in another thread and someone mentioned DND which was "off topic".

i looked at it, bought it right away. So sometimes it's not so bad. Come talk to me in a year when PHM is +0.85 cents

Bullboard Posts

Covalon Technologies posts third profitable quarter in a row